{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T21:30:59Z","timestamp":1790112659799,"version":"4.0.1"},"reference-count":73,"publisher":"Elsevier BV","issue":"1-3","license":[{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1016\/j.schres.2011.09.016","type":"journal-article","created":{"date-parts":[[2011,10,17]],"date-time":"2011-10-17T18:05:01Z","timestamp":1318874701000},"page":"54-62","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":97,"title":["Treatment resistant schizophrenia and response to antipsychotics: A review"],"prefix":"10.1016","volume":"133","author":[{"given":"Takefumi","family":"Suzuki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Remington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit H.","family":"Mulsant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarek K.","family":"Rajji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariel","family":"Graff-Guerrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Mamo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.schres.2011.09.016_bb0005","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1001\/archpsyc.60.12.1228","article-title":"Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected","volume":"60","author":"Agid","year":"2003","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.schres.2011.09.016_bb0010","series-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"1994"},{"key":"10.1016\/j.schres.2011.09.016_bb0015","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1176\/appi.ajp.162.3.441","article-title":"Remission in schizophrenia: proposed criteria and rationale for consensus","volume":"162","author":"Andreasen","year":"2005","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2011.09.016_bb0020","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1176\/appi.ajp.158.8.1305","article-title":"A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia","volume":"158","author":"Azorin","year":"2001","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2011.09.016_bb0025","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1001\/archpsyc.1988.01800250095013","article-title":"Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses","volume":"45","author":"Baldessarini","year":"1988","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.schres.2011.09.016_bb0030","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.pnpbp.2003.09.033","article-title":"Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia","volume":"28","author":"Bitter","year":"2004","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.schres.2011.09.016_bb0035","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1176\/ajp.155.4.499","article-title":"Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. The Risperidone Study Group","volume":"155","author":"Bondolfi","year":"1998","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2011.09.016_bb0040","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1176\/appi.ajp.2010.09101406","article-title":"Prediction of real-world functional disability in chronic mental disorders: a comparison of schizophrenia and bipolar disorder","volume":"167","author":"Bowie","year":"2010","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2011.09.016_bb0050","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0006-3223(98)00291-1","article-title":"Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia","volume":"45","author":"Breier","year":"1999","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.schres.2011.09.016_bb0045","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1176\/ajp.151.1.20","article-title":"Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia","volume":"151","author":"Breier","year":"1994","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2011.09.016_bb0055","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/schbul\/sbp116","article-title":"The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements","volume":"36","author":"Buchanan","year":"2010","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2011.09.016_bb0060","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1046\/j.1440-1819.2003.01151.x","article-title":"Olanzapine in Chinese treatment-resistant patients with schizophrenia: an open-label, prospective trial","volume":"57","author":"Chiu","year":"2003","journal-title":"Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.schres.2011.09.016_bb0065","doi-asserted-by":"crossref","first-page":"451","DOI":"10.4088\/JCP.v64n0416","article-title":"Clozapine in treatment-resistant patients with schizophrenia, schizoaffective disorder, or psychotic bipolar disorder: a naturalistic 48-month follow-up study","volume":"64","author":"Ciapparelli","year":"2003","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2011.09.016_bb0070","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1176\/ajp.155.7.914","article-title":"Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia","volume":"155","author":"Conley","year":"1998","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2011.09.016_bb0075","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/01.wnf.0000172993.89879.0f","article-title":"Risperidone, quetiapine, and fluphenazine in the treatment of patients with therapy-refractory schizophrenia","volume":"28","author":"Conley","year":"2005","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.schres.2011.09.016_bb0080","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1097\/01.jcp.0000117422.05703.ae","article-title":"Dose response and dose equivalence of antipsychotics","volume":"24","author":"Davis","year":"2004","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2011.09.016_bb0085","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S0149-2918(00)80082-X","article-title":"The effectiveness of olanzapine in treatment-refractory schizophrenia when patients are nonresponsive to or unable to tolerate clozapine","volume":"22","author":"Dossenbach","year":"2000","journal-title":"Clin. Ther."},{"key":"10.1016\/j.schres.2011.09.016_bb0090","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/00004850-200015030-00001","article-title":"A comparison of the effects of quetiapine (\u2018seroquel\u2019) and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment. PRIZE Study Group","volume":"15","author":"Emsley","year":"2000","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2011.09.016_bb0095","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1055\/s-2007-979291","article-title":"An open comparison of clozapine and risperidone in treatment-resistant schizophrenia","volume":"31","author":"Flynn","year":"1998","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.schres.2011.09.016_bb0100","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1093\/schbul\/sbn094","article-title":"Negative symptoms in schizophrenia: avolition and Occam's razor","volume":"36","author":"Foussias","year":"2010","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2011.09.016_bb0105","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1176\/appi.ajp.2009.09060802","article-title":"International consensus study of antipsychotic dosing","volume":"167","author":"Gardner","year":"2010","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2011.09.016_bb0110","first-page":"218","article-title":"ECDEU Assessment Manual for Psychopharmacology-Revised (DHEW Publ No ADM 76\u2013338)","author":"Guy","year":"1976"},{"key":"10.1016\/j.schres.2011.09.016_bb0115","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1093\/schbul\/sbn171","article-title":"Toward a terminology for functional recovery in schizophrenia: is functional remission a viable concept?","volume":"35","author":"Harvey","year":"2009","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2011.09.016_bb0120","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1093\/schbul\/10.3.388","article-title":"The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome","volume":"10","author":"Heinrichs","year":"1984","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2011.09.016_bb0125","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/00004850-199705000-00001","article-title":"A double-blind comparative study of clozapine versus chlorpromazine on Chinese patients with treatment-refractory schizophrenia","volume":"12","author":"Hong","year":"1997","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2011.09.016_bb0130","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.eurpsy.2009.02.005","article-title":"Early improvement as a predictor of remission and response in schizophrenia: results from a naturalistic study","volume":"24","author":"J\u00e4ger","year":"2009","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.schres.2011.09.016_bb0135","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1176\/appi.ajp.162.1.130","article-title":"Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial","volume":"162","author":"Josiassen","year":"2005","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2011.09.016_bb0140","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","article-title":"Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine","volume":"45","author":"Kane","year":"1988","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.schres.2011.09.016_bb0145","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1001\/archpsyc.58.10.965","article-title":"Clozapine and haloperidol in moderately refractory schizophrenia: a 6-month randomized and double-blind comparison","volume":"58","author":"Kane","year":"2001","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.schres.2011.09.016_bb0150","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/01.yic.0000182114.65134.81","article-title":"Efficacy and tolerability of ziprasidone in patients with treatment-resistant schizophrenia","volume":"21","author":"Kane","year":"2006","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2011.09.016_bb0155","doi-asserted-by":"crossref","first-page":"213","DOI":"10.4088\/JCP.v68n0206","article-title":"Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine","volume":"68","author":"Kane","year":"2007","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2011.09.016_bb0160","doi-asserted-by":"crossref","first-page":"194","DOI":"10.4088\/JCP.07m03733yel","article-title":"A double-blind, randomized study comparing the efficacy and safety of sertindole and risperidone in patients with treatment-resistant schizophrenia","volume":"72","author":"Kane","year":"2011","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2011.09.016_bb0165","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2011.09.016_bb0170","first-page":"309","article-title":"Treatment of neuroleptic-resistant schizophrenic relapse","volume":"29","author":"Kinon","year":"1993","journal-title":"Psychopharmacol. Bull."},{"key":"10.1016\/j.schres.2011.09.016_bb0175","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1093\/schbul\/sbp044","article-title":"Validating measures of real-world outcome: the results of the VALERO Expert Survey and RAND panel","volume":"37","author":"Leifker","year":"2011","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2011.09.016_bb0180","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1093\/schbul\/sbn035","article-title":"Implications of clinical trial design on sample size requirements","volume":"34","author":"Leon","year":"2008","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2011.09.016_bb0185","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1192\/bjp.bp.109.075366","article-title":"Clinical relevance of findings in trials of antipsychotics: systematic review","volume":"198","author":"Lepping","year":"2011","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.schres.2011.09.016_bb0190","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.schres.2005.04.008","article-title":"What does the PANSS mean?","volume":"79","author":"Leucht","year":"2005","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2011.09.016_bb0195","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1038\/sj.npp.1301147","article-title":"Linking the PANSS, BPRS, and CGI: clinical implications","volume":"31","author":"Leucht","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.schres.2011.09.016_bb0200","doi-asserted-by":"crossref","first-page":"352","DOI":"10.4088\/JCP.v68n0301","article-title":"Early prediction of antipsychotic nonresponse among patients with schizophrenia","volume":"68","author":"Leucht","year":"2007","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2011.09.016_bb0205","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1600-0447.2008.01308.x","article-title":"Definitions of response and remission in schizophrenia: recommendations for their use and their presentation","volume":"s438","author":"Leucht","year":"2009","journal-title":"Acta Psychiatr. Scand. Suppl."},{"key":"10.1016\/j.schres.2011.09.016_bb0210","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.biopsych.2010.01.012","article-title":"Elaboration on the early-onset hypothesis of antipsychotic drug action: treatment response trajectories","volume":"68","author":"Levine","year":"2010","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.schres.2011.09.016_bb0215","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1176\/ajp.151.12.1744","article-title":"Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome","volume":"151","author":"Lieberman","year":"1994","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2011.09.016_bb0220","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1097\/00004714-200108000-00014","article-title":"Olanzapine for schizophrenia refractory to typical and atypical antipsychotics: an open-label, prospective trial","volume":"21","author":"Lindenmayer","year":"2001","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2011.09.016_bb0225","doi-asserted-by":"crossref","first-page":"931","DOI":"10.4088\/JCP.v63n1011","article-title":"Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study","volume":"63","author":"Lindenmayer","year":"2002","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2011.09.016_bb0230","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.eurpsy.2005.09.009","article-title":"Meta-analysis of drop-out rates in randomised clinical trials, comparing typical and atypical antipsychotics in the treatment of schizophrenia","volume":"21","author":"Martin","year":"2006","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.schres.2011.09.016_bb0235","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1001\/archpsyc.1989.01810070098017","article-title":"Duration of a clozapine trial in neuroleptic-resistant schizophrenia","volume":"46","author":"Meltzer","year":"1989","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.schres.2011.09.016_bb0240","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1185\/03007999709113338","article-title":"Treatment-resistant schizophrenia \u2014 the role of clozapine","volume":"14","author":"Meltzer","year":"1997","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.schres.2011.09.016_bb0245","doi-asserted-by":"crossref","first-page":"274","DOI":"10.4088\/JCP.v69n0214","article-title":"A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia","volume":"69","author":"Meltzer","year":"2008","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2011.09.016_bb0250","first-page":"97","article-title":"The brief psychiatric rating scale (BPRS): recent development in ascertainment and scaling","volume":"24","author":"Overall","year":"1988","journal-title":"Psychopharmacol. Bull."},{"key":"10.1016\/j.schres.2011.09.016_bb0255","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1093\/schbul\/sbn005","article-title":"Dropout rates in randomized clinical trials of antipsychotics: a meta-analysis comparing first- and second-generation drugs and an examination of the role of trial design features","volume":"35","author":"Rabinowitz","year":"2009","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2011.09.016_bb0260","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2165\/11530250-000000000-00000","article-title":"Progress in defining optimal treatment outcome in schizophrenia","volume":"24","author":"Remington","year":"2010","journal-title":"CNS Drugs"},{"key":"10.1016\/j.schres.2011.09.016_bb0265","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJM199709183371202","article-title":"A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia","volume":"337","author":"Rosenheck","year":"1997","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.schres.2011.09.016_bb0270","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.schres.2009.05.002","article-title":"Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: the MOZART study","volume":"113","author":"Sacchetti","year":"2009","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2011.09.016_bb0275","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/j.pnpbp.2007.06.002","article-title":"Clinical predictors of therapeutic response to clozapine in a sample of Turkish patients with treatment-resistant schizophrenia","volume":"31","author":"Semiz","year":"2007","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.schres.2011.09.016_bb0280","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1017\/S1461145705005961","article-title":"A meta-analysis of profile and time-course of symptom change in acute schizophrenia treated with atypical antipsychotics","volume":"9","author":"Sherwood","year":"2006","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.schres.2011.09.016_bb0285","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s002130050028","article-title":"Relationship between plasma concentrations of clozapine and norclozapine and therapeutic response in patients with schizophrenia resistant to conventional neuroleptics","volume":"148","author":"Spina","year":"2000","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.schres.2011.09.016_bb0315","unstructured":"Suzuki, T., in press. Which rating scales are regarded as \u2018the standard\u2019 in clinical trials for schizophrenia? A critical review. Psychopharmacol. Bull. http:\/\/www.medworksmedia.com\/."},{"key":"10.1016\/j.schres.2011.09.016_bb0290","first-page":"323","article-title":"Reducing the dose of antipsychotic medications for those who had been treated with high-dose antipsychotic polypharmacy: an open study of dose reduction for chronic schizophrenia","volume":"18","author":"Suzuki","year":"2003","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2011.09.016_bb0295","first-page":"80","article-title":"Treatment target in schizophrenia: a critical review and a clinical suggestion","volume":"41","author":"Suzuki","year":"2008","journal-title":"Psychopharmacol. Bull."},{"key":"10.1016\/j.schres.2011.09.016_bb0300","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.schres.2008.08.013","article-title":"Novel rating scales for schizophrenia \u2014 Targeted Inventory on Problems in Schizophrenia (TIP-Sz) and Functional Assessment for Comprehensive Treatment of Schizophrenia (FACT-Sz)","volume":"106","author":"Suzuki","year":"2008","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2011.09.016_bb0305","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1002\/hup.1073","article-title":"Augmentation of atypical antipsychotics with valproic acid. An open-label study for most difficult patients with schizophrenia","volume":"24","author":"Suzuki","year":"2009","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.schres.2011.09.016_bb0310","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1097\/JCP.0b013e3181f0bae1","article-title":"Magnitude of rater differences in assessment scales for schizophrenia","volume":"30","author":"Suzuki","year":"2010","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2011.09.016_bb0320","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1192\/bjp.bp.110.083907","article-title":"Time course of improvement with antipsychotic medication in treatment-resistant schizophrenia","volume":"199","author":"Suzuki","year":"2011","journal-title":"Br. J. Psychiatry."},{"key":"10.1016\/j.schres.2011.09.016_bb0325","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/S0006-3223(00)01026-X","article-title":"Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine","volume":"49","author":"Tollefson","year":"2001","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.schres.2011.09.016_bb0330","first-page":"495","article-title":"Review on vocational predictors: a systematic review of predictors of vocational outcomes among individuals with schizophrenia: an update since 1998","volume":"44","author":"Tsang","year":"2010","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"10.1016\/j.schres.2011.09.016_bb0335","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1176\/appi.ajp.159.2.255","article-title":"Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder","volume":"159","author":"Volavka","year":"2002","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2011.09.016_bb0340","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1177\/0269881108093588","article-title":"Outcomes for schizophrenia patients with clozapine treatment: how good does it get?","volume":"23","author":"Wheeler","year":"2009","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.schres.2011.09.016_bb0345","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1176\/ajp.156.9.1374","article-title":"Risperidone in treatment-refractory schizophrenia","volume":"156","author":"Wirshing","year":"1999","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2011.09.016_bb0350","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/00004850-200111000-00002","article-title":"Risperidone versus haloperidol in the treatment of acute exacerbations of chronic inpatients with schizophrenia: a randomized double-blind study","volume":"16","author":"Zhang","year":"2001","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2011.09.016_bb0355","doi-asserted-by":"crossref","first-page":"878","DOI":"10.4088\/JCP.v62n1107","article-title":"A double-blind, placebo-controlled trial of extract of Ginkgo biloba added to haloperidol in treatment-resistant patients with schizophrenia","volume":"62","author":"Zhang","year":"2001","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2011.09.016_bb0360","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.schres.2006.07.010","article-title":"Beneficial effects of ondansetron as an adjunct to haloperidol for chronic, treatment-resistant schizophrenia: a double-blind, randomized, placebo-controlled study","volume":"88","author":"Zhang","year":"2006","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2011.09.016_bb0365","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1177\/106002809302701016","article-title":"Pharmacoepidemiology of clozapine in 202 inpatients with schizophrenia","volume":"27","author":"Zito","year":"1993","journal-title":"Ann. Pharmacother."}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996411004956?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996411004956?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:23:30Z","timestamp":1760297010000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996411004956"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":73,"journal-issue":{"issue":"1-3","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["S0920996411004956"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2011.09.016","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2011,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment resistant schizophrenia and response to antipsychotics: A review","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2011.09.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}